ArticleClinical kidney journal2025
Anti-nephrin antibody: a potential biomarker of minimal change disease.
Article in Clinical kidney journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Current status and research hotspots of pediatric nephrotic syndrome: a bibliometric analysis (2011-2025).Frontiers in pediatrics · 2026Pooled it
- Association between anti-nephrin autoantibodies and disease activity in minimal change disease.Annals of medicine · 2026Article
- Immune dysregulation in pediatric cancer-associated nephrotic syndrome: current insights.Pediatric nephrology (Berlin, Germany) · 2026Review
- Anti-CD20 Therapies and Antinephrin Autoantibodies in IgA Nephropathy With Minimal Change Disease.Kidney international reports · 2026Article
- Anti-nephrin antibodies in pediatric nephrotic syndrome: a new paradigm.Pediatric nephrology (Berlin, Germany) · 2026Review
- Dysregulated Protease Homeostasis Defines Primary FSGS.Kidney360 · 2026Article
- Serum Factors in Primary Podocytopathies.Antibodies (Basel, Switzerland) · 2025Review
- From slit diaphragm to autoantigen formation: a SUMOylation-based perspective on minimal change disease.Frontiers in nephrology · 2025Article
- Quo Vadis Standardization of Anti-Nephrin Antibody Detection?Glomerular diseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Minimal change disease (MCD) is a common pathological type of nephrotic syndrome in children and adults, and the mechanisms remain obscure. The diagnosis of MCD still relies on renal biopsy, lacking effective biological markers. This study explores the diagnostic value of circulating anti-nephrin antibody in MCD patients and evaluates the correlation with disease activity indicators such as proteinuria. Methods: The study included 108 adult patients with glomerular disease, including 36 with MCD, 16 with primary focal segmental glomerulosclerosis (FSGS), 20 with primary membranous nephropathy (MN), 17 with diabetic nephropathy (DN) and 19 with immunoglobulin A nephropathy (IgAN). Twenty healthy volunteers were included. Circulating anti-nephrin antibody was detected by indirect immunofluorescence method of cell-based assay. The receiver-operating characteristic (ROC) curve was used to evaluate the role of circulating anti-nephrin antibody in the diagnosis of MCD. The correlations between anti-nephrin antibody and clinical parameters were analyzed. Results: The prevalence of circulating anti-nephrin antibody was 19.44% (7 of 36) in MCD and 26.92% (7 of 26) in MCD patients with nephrotic proteinuria, which was higher than in FSGS, PMN, DN, IgAN and healthy volunteers. The ROC curve showed that the sensitivity of anti-nephrin antibody used in the diagnosis of MCD was 19.4% and the specificity was 97.8%. The MCD patients with positive anti-nephrin antibody had heavier proteinuria and higher serum lipid levels, while having lower serum albumin and blood IgG levels. Anti-nephrin antibody might turn to negative when the MCD patient had a response to therapy. Conclusions: Circulating anti-nephrin antibody may be a potential biomarker of MCD and may play a role in the MCD diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.